Dr. Buchanan will helm Belharra's research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

Cancer metastasis -- the spread of cancer to other organs -- is the leading cause of death among cancer patients. Researchers have now uncovered a 'genetic signature' of 177 genes shared across ...

A new era, where AI is at the centre of the drug discovery process is emerging, says Charlotte Deane, a professor of ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Bioanalysis is also used to monitor therapeutic responses by evaluating drug levels, biomarkers, and physiological changes ...

Multi-year program advancing translational medical science research and educationCAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- FUJIFILM Holdings America Corporation (Fujifilm), today celebrates ...

This article provides examples of how AI is helping to shape drug discovery, from drug design through to clinical trials.

Breast Cancer Now said olaparib will be an ‘valuable alternative’ for patients with a certain type of secondary breast cancer ...